UK markets open in 7 hours 14 minutes

Biotest Aktiengesellschaft (0N70.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
26.80-0.30 (-1.11%)
At close: 2:55PM GMT

Biotest Aktiengesellschaft

Landsteinerstrasse 5
Dreieich 63303
Germany
49 6103 801 0
http://www.biotest.com

Sector(s)
Industry
Full-time employees1,871

Key executives

NameTitlePayExercisedYear born
Dr. Michael RamrothChairman of the Management Board, CEO & CFO1.11MN/A1961
Dr. Georg FloßCOO & Member of the Board of Management882kN/AN/A
Dr. Monika ButtkereitHead of Investor RelationsN/AN/AN/A
Dr. Christina ErbHead of Corp. HRN/AN/AN/A
Dr. Katrin BernösterHead of the Project Management OrganisationN/AN/AN/A
Mr. Peter SeithHead of Quality OperationsN/AN/AN/A
Dr. Jörg SchüttrumpfHead of R&DN/AN/AN/A
Dr. Wolfgang MöllerHead of Devel. - Plasma ProteinN/AN/AN/A
Dr. Hermann KeuperSr. VP of ManufacturingN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; IgG Next Genration for primary immune deficiency and immunothrombocytopenia; Varitect for the treatment of varicella zoster virus infections; Zutectra for hepatitis B re-infection prophylaxis after liver transplantation; and Cytotect 70(BT-094) for prevention of cytomegalovirus infection in the foetus during pregnancy with mother's CMV infection. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Tiancheng International Investment Limited.

Corporate governance

Biotest Aktiengesellschaft’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.